Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Publication year range
1.
Eur J Pharmacol ; 842: 270-280, 2019 Jan 05.
Article in English | MEDLINE | ID: mdl-30287152

ABSTRACT

The pathophysiology of ischemic stroke involves multiple events such as inflammation and oxidative stress which will lead to neuronal death and cognitive deficits. The (-)-α-bisabolol is a monocyclic sesquiterpene alcohol found in various plants and mainly in Matricaria chamomilla, which exerts antioxidant, anti-inflammatory, and anti-apoptotic activities. The aim of this work was to investigate the neuroprotective effects of (-)-α-bisabolol in mice underwent permanent occlusion of the middle cerebral artery (pMCAO). Animals were treated with (-)-α-bisabolol (50, 100 and 200 mg/kg/day, orally) or vehicle (3% tween 80) one day before and 1 h after pMCAO and the treatment continued once daily for the following five days. The treatment with (-)-α-bisabolol (100 and 200 mg/kg) significantly reduced the infarcted area and neurological deficits caused by pMCAO. (-)-α-bisabolol at the 200 mg/kg dose increased cell viability and decreased neuronal degeneration, as evaluated by cresyl violet and Fluoro-Jade C stainings, respectively. (-)-α-bisabolol also increased the locomotor activity which was reduced by cerebral ischemia and improved pMCAO-induced working, spatial, object recognition, and aversive memories deficits. (-)-α-bisabolol (200 mg/kg) significantly prevented the increase of myeloperoxidase (MPO) activity, TNF-α immunoreactivity in the temporal cortex, and the increase of iNOS both in the temporal cortex and in the striatum. (-)-α-bisabolol treatment also prevented astrogliosis in these areas. These data showed that (-)-α-bisabolol provides neuroprotective action probably due to its anti-inflammatory activity, although other mechanisms cannot be discarded.


Subject(s)
Infarction, Middle Cerebral Artery/complications , Infarction, Middle Cerebral Artery/pathology , Memory Disorders/drug therapy , Memory Disorders/metabolism , Neurons/drug effects , Neuroprotective Agents/pharmacology , Sesquiterpenes/pharmacology , Animals , Biomarkers/metabolism , Cell Death/drug effects , Inflammation/metabolism , Male , Maze Learning/drug effects , Memory Disorders/complications , Memory Disorders/pathology , Mice , Monocyclic Sesquiterpenes , Neurons/pathology , Neuroprotective Agents/therapeutic use , Sesquiterpenes/therapeutic use
2.
Behav Brain Res ; 312: 321-32, 2016 10 01.
Article in English | MEDLINE | ID: mdl-27353856

ABSTRACT

BACKGROUND: Cerebral ischemia is a common disease and one of the most common causes of death and disability worldwide. The lack of glucose and oxygen in neuronal tissue leads to a series of inflammatory events, culminating in neuronal death. Eriodictyol is a flavonoid isolated from the Chinese herb Dracocephalum rupestre that has been proven to have anti-inflammatory properties. HYPOTHESIS/PURPOSE: Thus, the present study was designed to explore whether eriodictyol has neuroprotective effects against the neuronal damage, motor and memory deficits induced by permanent middle cerebral artery occlusion (pMCAO) in mice. STUDY DESIGN: Animals were orally treated with eriodictyol (1, 2 and 4mg/kg) or vehicle (saline) 30min before pMCAO, 2h after, and then once daily for the following five days. METHODS: The parameters studied were neuronal viability, brain infarcted area; sensorimotor deficits; exploratory activity; working and aversive memory; myeloperoxidase (MPO) activity; TNFα, iNOS and GFAP immunoreactivity. RESULTS: The treatment with eriodictyol prevented neuronal death, reduced infarct area and improved neurological and memory deficits induced by brain ischemia. The increase of MPO activity and TNF-α, iNOS and GFAP expression were also reduced by eriodictyol treatment. CONCLUSION: These findings demonstrate that eriodictyol exhibit promising neuroprotection effects against the permanent focal ischemia cerebral injury in the mice experimental model and the underlying mechanisms might be mediated through inhibition of neuroinflammation.


Subject(s)
Brain Ischemia/complications , Brain/drug effects , Encephalitis/metabolism , Encephalitis/prevention & control , Flavanones/administration & dosage , Neuroprotective Agents/administration & dosage , Stroke/complications , Animals , Astrocytes/drug effects , Brain/metabolism , Brain/pathology , Cell Survival/drug effects , Disease Models, Animal , Encephalitis/etiology , Exploratory Behavior/drug effects , Locomotion/drug effects , Male , Memory, Short-Term/drug effects , Mice , Neurons/drug effects , Nitric Oxide Synthase Type II/metabolism , Peroxidase/metabolism , Tumor Necrosis Factor-alpha/metabolism
3.
Fortaleza; s.n; 2016. 93 p. ilus, tab.
Thesis in Portuguese | LILACS | ID: biblio-972029

ABSTRACT

O Acidente Vascular Encefálico (AVE) é definido como um quadro clínico de déficit neurológico que pode perdurar ou exceder as primeiras vinte e quatro horas do evento. A Organização Mundial de Saúde (OMS) revela que entre os anos de 2000 e 2011, o AVE apresentou-se como a segunda principal causa de óbitos em todo o mundo. Segundo o Ministério da Saúde, o AVE é a principal causa de morte no Brasil. É causado pela diminuição da perfusão sanguínea com depleção de oxigênio e glicose ao cérebro, causando redução dos níveis de ATP e predispondo a eventos como: excitotoxicidade glutamatérgica, influxo exacerbado de Ca++, estresse oxidativo, inflamação e apoptose, resultando em morte neuronal. O eriodictiol (3‟,4‟,5,7-tetrahidroxiflavanona) é um flavonóide encontrado na erva chinesa (Dracocephalum rupestre). Possui atividades anti-inflamatória, antioxidante e antiapoptótica já reportadas. O objetivo deste trabalho foi estudar os efeitos do eriodictiol sobre o dano neuronal, déficits de memória e resposta infamatória de camundongos submetidos à isquemia cerebral focal por oclusão permanente da artéria cerebral média (pMCAO). Os animais foram tratados oralmente com eriodictiol (1, 2 e 4 mg / kg) ou veículo (5% Tween 80 em salina 0,9%) 30 min antes, 2 horas depois da pMCAO e diariamente durante 4 dias. A pMCAO promoveu dano cerebral nos animais isquemiados, sendo esse comprovado, por meio da detecção do aumento significativo nas percentagens das áreas de infarto, pelos déficits sensório-motores observados e pela perda da viabilidade neuronal. O eriodictiol reduziu a área de infarto cerebral nas doses de 1, 2 e 4 mg/kg e preveniu os animais isquemiados dos déficits neurológicos 24h após pMCAO...


Stroke is defined as a clinical neurological deficit that may last or exceed the first twenty-four hours of the event. The World Health Organization (WHO) reveals that between 2000 and 2011, the Stroke was presented as the second leading cause of death worldwide. According to the Ministry of Health, stroke is the leading cause of death in Brazil. It is caused by decreased blood perfusion depleted of oxygen and glucose to the brain,causing ATP reduction levels and predisposing to events such as glutamatergic excitotoxicity, exacerbated influx of Ca++, oxidative stress, inflammation and apoptosis, resulting in neuronal death. The eriodictyol (3 ', 4', 5,7-tetrahydroxyflavanone) is a flavonoid found in the Chinese herb (Dracocephalum rupestre) having anti-inflammatory, antioxidant and anti-apoptotic effects previously reported. The objective of this study was to analyze the effects of eriodictyol on neuronal damage, memory deficits and inflammatory-response of mice subjected to focal cerebral ischemia by permanent meddle cerebral artery occlusion (pMCAO). The animals were treated orally with eriodictyol (1, 2 and 4 mg / kg) or vehicle (5% Tween 80 in saline 0,9%) 30 minutes before, 2 hours after the pMCAO and daily for 4 days. The promoted pMCAOischemic brain damage in animals, this being confirmed by means of detection of a significant increase in the percentage of infarcted areas, the observed sensorimotor deficits and loss of neuronal viability. The eriodictyol reduced the area of cerebral infarction in doses of 1, 2 and 4 mg / kg and prevented the animal-ischemic neurological deficits 24h post-pMCAO...


Subject(s)
Humans , Inflammation , Brain Ischemia , Memory
SELECTION OF CITATIONS
SEARCH DETAIL
...